
Biogen reports 82.5% stability in LEQEMBI study
- Biogen and Eisai announced that 82.5% of early Alzheimer's patients taking LEQEMBI remained stable or improved over 17 months.
- Safety data showed amyloid-related imaging abnormalities occurred in 12.3% of patients, maintaining consistency with existing FDA label expectations.
- The companies are using the ongoing three-year LEADER study to track the real-world efficacy and safety of the treatment.
Biogen (NASDAQ:BIIB) and Eisai reported that 82.5% of LEQEMBI patients remained stable or improved over 17 months.
The real-world LEADER study data presented at AAIC 2026 tracked 427 early Alzheimer’s patients across the United States.
The data showed 75.9% of these patients remained stable, while 6.6% improved from mild dementia to mild cognitive impairment.
Nearly 87% of patients chose to continue treatment, and 12.3% experienced mostly mild amyloid-related imaging abnormalities.
Biogen stated that treatment benefits remained consistent across different patient demographics and specific genetic subgroups.
The companies also reported stable results for smaller subgroups testing monthly intravenous and weekly subcutaneous maintenance doses.
Frequently asked questions
More from United States
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab
DataMeds AI issues 630,000 shares in cancer partnership
CoinShares net income improves 27% to $39.6 million
newcleo revenue skyrockets 26% to €10 million in Q3